CV risk profile and treatment characteristics of patients with rheumatoid arthritis in the biologics and ERA cohorts. Values are n (%) unless otherwise specified.
| Characteristics | Overall, n = 170 | Biologics, n = 63 | ERA, n = 107 |
|---|---|---|---|
| HTN | 44 (26) | 23 (37) | 21 (20) |
| Blood pressure ≥ 140/90 at first visit and no prior diagnosis of HTN | 23 (14) | 4 (6) | 19 (18) |
| Diabetes | 11 (7) | 4 (6) | 7 (7) |
| Dyslipidemia | 26 (15) | 10 (16) | 16 (15) |
| Obesity, BMI ≥ 30 | 43 (25) | 14 (22) | 29 (27) |
| BMI, mean (SD) | 27.3 (4.9) | 26.7 (5.1) | 27.5 (4.9) |
| Family history of CVD | 4 (2) | 1 (2) | 3 (3) |
| Missing information on family history | 58 (34) | 41 (65) | 17 (16) |
| Current smoker | 35 (21) | 8 (13) | 27 (25) |
| Ex-smoker | 56 (33) | 26 (41) | 30 (28) |
| Non-smoker | 69 (41) | 25 (40) | 44 (41) |
| Missing smoking data | 10 (6) | 4 (6) | 6 (6) |
| Baseline FRS, n = 59 FRS calculated* | |||
| FRS low | 39 (66) | 6 (75) | 33 (65) |
| FRS intermediate | 13 (22) | 2 (25) | 11 (22) |
| FRS high | 7 (11) | 0 (0) | 7 (14) |
| FRS could not be calculated, but patients were eligible for FRS estimation, n = 134 | |||
| FRS could not be calculated | 75 (56) | 39 (83) | 36 (41) |
| Baseline CV risk factor treatment at end of first visit | |||
| Aspirin | 19 (11) | 9 (14) | 10 (10) |
| Statin** | 19 (11), n = 168 | 7 (11), n = 62 | 12 (11), n = 12 |
| Antihypertensive agents, any | 40 (24) | 21 (33) | 19 (18) |
↵* Baseline FRS was calculated with baseline variables at first visit using lipid values from up to 6 months prior to first visit and 1 year after.
↵** Two patients had major missing and/or conflicting information in the chart and statin use and dyslipidemia history could not be determined. CV: cardiovascular; ERA: early rheumatoid arthritis; HTN: hypertension; BMI: body mass index; CVD: CV disease; FRS: Framingham Risk Score.